Novo Nordisk A/S: Dwarfism, Pituitary trials
The registry lists 27 Dwarfism, Pituitary studies with Novo Nordisk A/S as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 1 5Phase 3 11Phase 4 2No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical ParametersEnrolling by invitationNCT06709040
- A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety InformationEnrolling by invitationNCT05718570
- A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone DeficiencyCompletedNCT03075644Phase 3Results posted
- A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone DeficiencyCompletedNCT02382939Phase 3Results posted
- Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.CompletedNCT02229851Phase 3Results posted
- Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®Active, not recruitingNCT05230550
- Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.CompletedNCT03212131Phase 1
- Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal FunctionCompletedNCT03186495Phase 1
- Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)CompletedNCT02580032
- Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)CompletedNCT02005198
- A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone DeficiencyCompletedNCT01973244Phase 1
- A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone DeficiencyCompletedNCT01706783Phase 1
- Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone DeficiencyTerminatedNCT01698944Phase 4
- French National Registry of Adults With Growth Hormone Deficiency Treated With SomatropinCompletedNCT01580605
- Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone DeficiencyCompletedNCT01563926Phase 3
- First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy SubjectsCompletedNCT01514500Phase 1
- Safety and Efficacy of Somatropin in Children With Growth Hormone DeficiencyCompletedNCT01502124Phase 3
- Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone DeficiencyCompletedNCT01109017
- An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)CompletedNCT01009905
- Observational Prospective Study on Patients Treated With Norditropin®CompletedNCT00960128
- Liquid Somatropin Formulation in Children With Growth Hormone DeficiencyCompletedNCT00567385Phase 4
- Growth Hormone Deficiency in Adults (GHDA)CompletedNCT00519558Phase 3
- Effect of Growth Hormone in Children With Growth Hormone DeficiencyCompletedNCT00262249Phase 3
- Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)CompletedNCT00184743Phase 3
- Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)CompletedNCT00184730Phase 3
- Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone DeficiencyCompletedNCT00184678Phase 3
- Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient ChildrenCompletedNCT00102817Phase 3